The incidence and mortality of esophageal squamous cell carcinoma are at the forefront in
China.Most part of patients are elderly. Concurrent chemoradiotherapy is the standard
treatment for unresectable locally advanced esophageal squamous cell carcinoma. Most elderly
patients cannot tolerate concurrent chemotherapy because of complications and other reasons.
Immunotherapy has definite efficacy and low toxicity in advanced esophageal squamous cell
carcinoma, and the results combined with radiotherapy have also been preliminarily reported.
Therefore, it is necessary to further explore the efficacy and safety of radiotherapy
combined with immunotherapy in elderly patients with esophageal squamous cell carcinoma.